BioMarin Pharmaceutical | BMRN - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 7.99B 2.44B 2026-09
Amgen USD 96.05B 409M 2026-09
Bayer EUR 113.47B 6.18B 2026-09
Biogen USD 32.05B 32.5M 2026-09
BioMarin Pharmaceutical USD 11.57B 154.21M 2026-09
Gilead Sciences USD 51.41B 2.05B 2026-09
Incyte USD 7.29B 585.39M 2026-09
Insmed USD 2.23B 123.49M 2026-09
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 5.63B 268.3M 2026-09
PTC Therapeutics USD 3.21B 42.76M 2026-09
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 44.41B 2.67B 2026-09
Roche Holding CHF 98.2B 2.5B 2026-06
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 129.06B 1.04B 2026-06
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
Ultragenyx Pharmaceutical USD 1.19B 77M 2026-09
United Therapeutics USD 7.03B 186M 2026-09
Vertex Pharmaceuticals USD 32.74B 5.31B 2026-09